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Abstract
Background: In a mouse model of viral induced atopic disease, expression of FceRI on dendritic cells is critical. While adult
human conventional (cDC) and plasmacytoid (pDC) dendritic cells have been shown to express FceRI, it is not known if this
receptor is expressed in childhood and how its expression is governed by IgE.
Methods: Following informed consent of subjects (n=27, aged 12–188 months), peripheral blood was stained for surface
expression of CD19, ILT7, CD1c, IgE, FceRI and analyzed by flow cytometry (cDC: CD19
2 ILT7
2 CD1c
+; pDC: CD19
2 ILT7
+
CD1c
2). Total and specific serum IgE levels to food and inhalant allergens were determined by ImmunoCAP, and the
relationship between FceRI expression on dendritic cells and sensitization, free IgE, cell bound IgE, and age was determined.
Results: Independent of sensitization status, FceRI expression was noted on cDC and pDC as early as 12 months of age.
Serum IgE level correlated with expression of FceRI on cDC, but not pDC. Based on the concentration of IgE, a complex
relationship was found between surface bound IgE and expression of FceRI on cDC. pDC exhibited a linear relationship of
FceRI expression and bound IgE that was consistent through all IgE concentrations.
Conclusions: In children, FceRI expression on cDC and pDC is modulated differently by serum and cell bound IgE. IgE
governance of FceRI expression on cDC depends upon a complex relationship. Further studies are needed to determine the
functional roles of FceRI on cDC and pDC.
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Introduction
Severe viral respiratory infections early in life are associated with
increased risk of asthma and atopic disease [1,2,3,4]. Using a mouse
model we defined potential mechanisms translating anti-viral
immune responses into atopic disease. Mice infected with the murine
type 1 parainfluenza virus develop an acute inflammatory response
and severe weight loss in the first week of infection. By 10 days post-
viral inoculation, the animals clear virus and begin to gain weight;
however, by day 21 post-inoculation they manifest chronic airway
hyper-reactivity and IL-13 dependent mucous cell metaplasia [5]. In
addition, exposure to an environmental antigen during the viral
infection is sufficient to generate IgE against the environmental
antigenleading to worseatopicdisease[6]. We have also shownthat a
similar response can occur in the gastrointestinal tract [7].
One hallmark of our model is that murine cDC and pDC do not
express FceRI except during severe viral infections, when cognate
interactions with a specific neutrophil subset drives FceRI
expression [8]. Cross-linking FceRI bound IgE on cDC leads to
recruitment of IL-13 producing Th2 cells driving the atopic
response. We have shown in humans that cross-linking IgE on
cDC produces CCL28, the same Th2 chemoattractant critical for
the mouse model [9]. Although adult human cDC and pDC are
known to express FceRI, very little is known about induction and
regulation of this receptor on human cDC and pDC from
children. We undertook this study to answer this issue.
Our study documents expression patterns of FceRI on peripheral
blood cDC and pDC in young children. While the receptors are
present early in life, we found a marked differential effect of low and
high IgE on cDC FceRI expression. This finding implies that cDC
expressed FceRI has disparate effects on cDC function depending
on serum level of IgE. Further, our data suggest that IgE control of
FceRI may be different in children compared to adults.
Methods
Experimental Design
A cross sectional time analysis was employed. Our primary goal
was to determine the age at which human cDC and pDC
expressed FceRI. Our secondary goal was to determine if
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32556sensitization to any food or inhalant allergen was associated with
FceRI and IgE expression.
Ethics Statement
This study was approved by the Children’s Hospital of
Wisconsin IRB. Parental written consent and subject verbal assent
was obtained before enrollment of subjects into this study.
Subjects
Once consent and assent was obtained, an abbreviated atopic
history was collected and venipuncture performed. Eligible
patients were children aged 1–15 years. Exclusion criteria were:
atopic dermatitis, persistent controlled asthma, uncontrolled
asthma, immunodeficiency, or any co-morbid disease; use of any
corticosteroids within the last month; current therapy with any
prescribed medication; use of any investigational agent in the last
30 days; women of childbearing age not on contraception or
women breastfeeding.
Sensitization status and total serum IgE determination
Total IgE and specific IgE levels to foods (casein, alpha-
lactalbumin, beta-lactoglobulin, cheese, egg white, cacao, soybean,
peanut, codfish, tuna, oat, rice, wheat) and aeroallergens (D.
farinae, D. pteronyssinus, cockroach, cat dander, dog dander, mouse
epithelium, rat epithelium, guinea pig epithelium, mouse serum
protein, rat serum protein, mouse urine protein, rat urine protein,
June grass, Alternaria tenuis, Cladosporium herbarum, Aspergillis fumigatus,
common ragweed, oak, birch, L. destructor) were determined by
ImmunoCAP (Quest Dignostics/IBT Laboratories). Sensitization
was defined as elevated serum specific IgE (.0.35 kU/L) to one or
more allergens tested.
Flow Cytometry
Immunophenotyping for evaluation of pDC and cDC was
performed within 6 hours of specimen collection. 100 mlo f
heparinized whole blood was stained with antibodies to human
CD19 (PerCP labeled clone SJ25C1, BD Biosciences), ILT7 (PE
labeled clone 17G10.2, eBioscience), and CD1c (APC labeled
clone BDCA-1, Miltenyi Biotec), as well as either antibodies
against FceRIa (FITC labeled clone AER-37, eBioscience) or IgE
(FITC labeled, Kirkegaard & Perry Laboratories, Inc.) for 15 min.
at room temperature. Erythrocytes were lysed with 2 ml
FACSLyse (BD Biosciences) and stained cells were washed with
PBS/0.1% NaN3 and fixed using 1% paraformaldehyde. Flow
cytometry (BD FACSCalibur) was performed with 5610
5 to
1610
6 total cellular events collected on each stained specimen.
cDC (also referred to as mDC-1) were identified as CD19
2/
ILT7
2/CD1c
+ and pDC identified as CD19
2/ILT7
+/CD1c
2.
This type of phenotyping strategy has been used before, as ILT7 is
a specific marker for pDC and CD19
2CD1c
+ cells have been
shown to be essentially all cDC [9,10,11,12,13,14,15,16]. Using
multi-color flow cytometry and Boolean gating strategy, the
expression of IgE and FceRIa were identified on the cDC and
pDC subsets and measured as fold mean florescence (fold MFI)
over individual isotype control background using CellQuest Pro
software (BD Biosciences) as shown in Figure 1A. Appropriate
isotype control antibodies were utilized, and calibration of FceRIa
expression (MEPE) was performed in each run using fluorescent
beads as described [17].
Statistical Analysis
Data were expressed as frequency and percent for categorical
variables and median and interquartile range for continuous
variables. Since the data were skewed, continuous variables were
compared using a Mann-Whitney test while doing 2 group
comparisons, and continuous variables were examined using
scatter plots and Pearson correlations. To investigate the inter-
related effects of variables on the outcomes of interest, a regression
tree analysis was done using Salford Systems’ CART software
(http://salford-systems.com/). Regression trees are a non-para-
metric approach where the data are split recursively into two
groups based on an optimizing function, until the specified limits
for subgroups are reached. A least absolute deviance from the
median was used as the optimizing function, with a limit of 10 in
any group to be split and 5 minimally needed for any group.
Linear regression was used to fit the data with linear or a
polynomial trend with normality of the error term checked with a
normal probability plot. cDC IgE was fit to serum IgE using a
non-linear regression for a sigmoidal type curve of the form 1/
(1+M/serum IgE)
m, where M is the (fitted) median value of cDC
IgE and m is the slope of the curve at that value. We fit linear
regression using SAS 9.2 and non-linear regression using JMP 9.0.
Given the relatively small sample, we did not use a bootstrap
approach or a holdout sample to validate the model results.
Therefore, these results will need to be validated on another
sample.
Results
Twenty-seven patients aged 12 to 188 months were recruited
from June through September 2009. All patients denied symptoms
of current allergic disease or respiratory tract infection. A
summary of subject characteristics is in Table 1. Subjects were
classified as sensitized based on ImmunoCap testing, with a single
positive test being considered ‘‘sensitized’’. No correlation was
noted between sensitization status and age, and other than total
serum IgE there was no significant difference in any demographic
information between the sensitized (n=12) and non-sensitized
subjects (n=15).
In a linear regression, we found that there was a moderate
correlation between age and serum IgE (r=0.53), with about 25%
of the variation of IgE explained by the linear relationship with
age. However, much of this relationship occurred in the non-
sensitized group (r=0.56) compared to the sensitized group
(r=0.29). This is not surprising, since serum IgE levels can
fluctuate, such as with viral infections, and our data were obtained
at only a single time point per subject [18].
Comparing the relative frequencies of conventional (cDC) and
plasmacytoid dendritic cells (pDC) amongst all of our subjects, we
found 1.26 (0.66–2.55) (median (IQR)) fold more cDC than pDC.
This ratio was not significantly different between sensitized and
non-sensitized subjects, nor did it correlate with age (data not
shown). While this ratio of cDC to pDC is lower than what has
been reported in older children, it is similar to what has been
reported in adult studies using a dendritic cell phenotyping
strategy similar to ours [14,15,19].
Conventional dendritic cells (cDC)
We initially hypothesized that similar to the rodent system,
peripheral blood cDC would not express FceRI early in life.
However, as shown in Figure 1B, FceRI expression was detected
on cDC at all ages. Given that viral infections have been shown to
upregulate expression of FceRI on dendritic cells, and that older
individuals likely had more viral infections, we supposed that
expression of the receptor would increase with age [18]. As shown
in Figure 1B, the age of the subject had a marginally linear
correlation to level of expression of FceRI on cDC (r=0.36,
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(r=0.53, p=0.08) but not non-sensitized (r=20.002, p=0.99)
subjects. Further, no association was found between family atopic
status and FceRI expression on cDC (p=0.42, data not shown).
In human mast cells and basophils, IgE modulates FceRI
expression [20]. In fact, in a study with anti-IgE the reduction in
IgE directly correlated with subsequent reduction of FceRI
expression on peripheral blood DC of adults [21]. We examined
the relationship between serum IgE and cDC expression of FceRI.
As shown in Figure 1C, there was a linear correlation (r=0.78,
p,0.0001) between serum IgE levels and cDC expression of
FceRI. This correlation held regardless of sensitization status
Figure 1. Expression of FceRI on cDC correlates with serum IgE but not with subject’s age. (A) Gating strategy used to identify expression
of FceRI and IgE on cDC and pDC. Cells were gated on scatter (R1) and lack of expression of CD19 (R2, PerCP negative). Those events that satisfied
both of these criteria were examined for expression of ILT7 (R3, PE positive) versus CD1c (R4, APC positive). Cells that were CD19
2ILT7
+CD1c
2 were
considered pDC and CD19
2ILT7
2CD1c
+ were considered cDC. The expression of FceRI (left histograms, FITC positive) or IgE (right histograms, FITC
positive) on these cells was then determined and compared to an appropriate isotype control. (B) Expression of FceRI on peripheral blood cDC was
determined by flow cytometry and compared to subject’s age or (C) serum IgE level. Data are presented as fold MFI FceRI versus age in months (B) or
serum IgE in kU/L (C), with non-sensitized subjects (n=15) in circles and sensitized subjects (n=12) in x’s. Sensitization was defined as having at least
one positive allergen specific IgE by ImmunoCAP.
doi:10.1371/journal.pone.0032556.g001
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subjects, p=0.01).
Sensitization status did not differentiate level of expression of
FceRI on cDC (Table 2). However, a regression tree analysis
revealed that when serum IgE was less than 60 kU/L, FceRI
expression was significantly higher on cDC from non-sensitized
subjects (median (IQR)=14.03 (13.2, 16.48) fold MFI) compared
to sensitized individuals (median (IQR)=12.05 (11.77, 12.74) fold
MFI), p=0.04.
Since bound IgE modulates expression of FceRI on human
mast cells and basophils, we examined the level of IgE on
peripheral blood cDC and correlated this with FceRI expression.
As shown in Figure 2A, the relationship between cDC expression
of FceRI and surface bound IgE was complex. With low level
staining of IgE (less than a fold MFI IgE expression of 12) there
was no relationship between surface bound IgE and FceRI.
However, at higher levels of surface bound IgE there was a direct
correlation between bound IgE and FceRI expression. Interest-
ingly, fitting curves to the data (the equations are shown in Table 3)
showed the relationship between cDC bound IgE and FceRI
expression to be different for sensitized and non-sensitized
individuals. In Figure 2A the relationship in sensitized individuals
appears to be exponential, while in non-sensitized it was more
sigmoidal. However, both curves appear to converge when
subjects expressed a fold MFI for IgE of 12 or greater. Analyzing
all of the data together (without making a distinction on
sensitization status) generated a curve that was sigmoidal and
the inflection point remained at a fold MFI IgE expression of 12
(Figure 2A, blue line).
By overlaying serum IgE levels, we found only subjects with a
serum IgE above 34–42 kU/L had a cDC fold IgE expression of
12 or greater (Figure 2B). These data suggest serum IgE drives
FceRI expression on peripheral blood cDC only when it crosses
this threshold level. Because the two curves converge (Figure 2A),
this effect appears to be unrelated to subject’s sensitization status.
Plasmacytoid dendritic cells (pDC)
Unlike peripheral blood cDC, pDC expression of FceRI was
minimal (median (IQR)=15.82 (12.74–21.05) versus 2.47 (1.47–
3.25) on cDC and pDC, respectively). In fact, 6 of the 27 subjects
appeared to have no expression of FceRI on their pDC (fold MFI
equal to or less than 1.0). As shown in Table 2, analogous to the
cDC data, sensitization status did not associate with level of
expression of FceRI on pDC. We also found no linear correlation
between age of the subject and pDC expression of FceRI
(Figure 3A; r=0.13, p=0.51 for all subjects; r=0.28, p=0.38
for sensitized subjects; and r=20.05, p=0.87 for non-sensitized
subjects). In sum, there was no correlation between a given
subject’s expression of FceRI on their cDC or pDC and age.
Unlike with cDC (Figure 1C), serum IgE levels did not correlate
with pDC expression of FceRI (Figure 3B, r=0.21, p=0.29 for all
subjects; r=0.42, p=0.17 for sensitized subjects; r=0.21, p=0.46
for non-sensitized subjects). Also, unlike cDC, pDC bound IgE
levels correlated linearly with pDC expression of FceRI in both
Table 1. Subject Characteristics.
Variable Non-sensitized (n=15) Sensitized
{ (n=12)
Age (months), median (range) 49 (12–139) 49 (12–188)
Male, n (%) 8 (53%) 5 (42%)
Personal History Atopy*, n(%) 14 (93%) 12 (100%)
Family History Atopy*, n(%) 12 (80%) 7 (58%)
Elevated Food specific IgE, n(%) 0 (0%) 9 (75%)
1
Elevated Inhalant allergen specific IgE, n(%) 0 (0%) 9 (75%)
*Atopy history: defined as self reported or MD diagnosed allergic rhinitis/hayfever/environmental allergies, asthma/wheeze, atopic dermatitis, food allergy. Family
history of atopy was based on self-reporting only.
{Sensitized: defined as any elevated food or inhalant serum specific IgE.
1Only 4 of these subjects had a clinical history suggestive of an allergy for the foods to which they had IgE against.
doi:10.1371/journal.pone.0032556.t001
Table 2. Comparison of Sensitized and Non-Sensitized Children for Dendritic Cell Expression of IgE and FceRI.
Median (IQR)
Variable Non-Sensitized (n=15) Sensitized (n=12) p-value
{
Age (month) 49 (28, 89) 49 (24.5, 95) .0.99
Serum IgE (kU/L) 9.5 (6, 42) 57.25 (22.3, 125) 0.003
pDC bound IgE (fold MFI) 2.42 (1.54, 2.74) 2.13 (1.15, 4.1) .0.999
pDC FceRI (fold MFI) 2.65 (1.59, 3.25) 2.02 (1.04, 3.25) 0.39
cDC bound IgE (fold MFI) 4.3 (2.68. 19.2) 17.33 (5.12, 33.5) 0.08
cDC FceRI (fold MFI) 14.37 (13.2, 17.8) 19.8 (12.1, 23.5) 0.48
{: Mann-Whitney test.
IQR: interquartile range, cDC: conventional dendritic cells, pDC: plasmacytoid dendritic cells.
doi:10.1371/journal.pone.0032556.t002
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e32556Figure 2. Correlation of cDC expression of FceRI with IgE. Expression of FceRI and IgE on the surface of cDC was determined by flow
cytometry. (A) Data are presented as fold MFI FceRI versus fold MFI IgE expression, with non-sensitized subjects (n=15) in red circles and sensitized
subjects (n=12) in black x’s. Note the difference in the slope of the fitted lines (non-sensitized subjects in red dotted line; sensitized subjects in black
solid line) above and below a fold MFI IgE of 12, suggesting that there is differential regulation of FceRI on cDC around this level of cell bound IgE. For
all subjects the data was fit with the following cubic equation (blue line): Ln(cDC FceRI)=2.26+0.72*ln(cDC IgE)-0.43*ln(cDC IgE)
2+0.082*ln(cDC IgE)
3);
r=0.86; p=0.045. For equations based on sensitization status, see Table 3. (B) Expression of cell bound IgE on cDC compared with serum (free) IgE
levels. Data are presented as in (A) with fold MFI IgE expression versus serum IgE (kU/L). Note that a cell bound IgE fold MFI of 12 correlates with a
serum IgE of around 38 (based on statistical fitting of the curve, this value could range between 34 and 42 kU/L).
doi:10.1371/journal.pone.0032556.g002
Table 3. Sensitization status regression models with significant Pearson correlations.
Regression Equation Pearson correlation (p-value)
Non-sensitized
pDC FceRI Vs. pDC IgE
Ln(pDC FceRI)=0.26+0.73*ln(pDC IgE) r=0.76 (p=0.001)
cDC FceRI Vs. cDC IgE
Ln(cDC FceRI)=2.49+0.13*ln(cDC IgE) r=0.65 (p=0.009)
Sensitized
pDC FceRI Vs. pDC IgE
Ln(pDC FceRI)=0.004+0.8*ln(pDC IgE) r=0.98 (p,0.0001)
cDC FceRI Vs. cDC IgE
Ln(cDC FceRI)=2.06+0.32*ln(cDC IgE) r=0.85 (p=0.0004)
Ln indicates the natural log transformation.
doi:10.1371/journal.pone.0032556.t003
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(r=0.98, p,0.0001). These data provide further evidence for a
direct association between bound IgE and FceRI expression in
pDC but not cDC, suggesting that regulation of FceRI is dissimilar
in cDC and pDC.
Discussion
Other studies have attempted to describe relationships between
serum IgE, cell-bound IgE, and FceRI expression on dendritic
cells [17,21]. These prior studies utilized adults, and did not
examine expression in children. There is one publication in the
literature that looked at children [22]. However, this report
examined older children and did not differentiate FceRI and IgE
staining on cDC and pDC, as they used CD11c and MHC-II as
markers for dendritic cells—markers that are insufficient to
distinguish cDC and pDC cells in humans [23]. Further, our
study utilized regression analysis to better understand the role of
FceRI on dendritic cells in children of various ages. We found that
as early as 12 months of age, regardless of sensitization status,
FceRI is expressed on peripheral blood cDC and pDC, although
pDC expression of some subjects was quite minimal. No
association between age and expression of IgE or FceRI was
found, indicating that our initial hypothesis was wrong (i.e., FceRI
expression on dendritic cells would correlate with age). Although
we do acknowledge that a longitudinal study would be more
appropriate to examine the relationship between age and receptor
expression. It does remain possible that early life developmental
control of FceRI expression exists before 12 months of age—
especially with pDC. Once induced, FceRI expression clearly can
be modulated by viral infections [18].
Interestingly, we found no association between sensitization
status and FceRI expression. We cannot equate sensitization with
atopy because we did not challenge our subjects with the
respective allergens. Further, it is quite possible that those subjects
we identified as non-sensitized were indeed making specific IgE—
just against antigens that were not included in our panels. For
these reasons our data may be different from two studies in adults
where atopic subjects were noted to have significantly higher
FceRI expression on cDC and pDC [15,21]. Our results do
corroborate those of the adult studies in the fact that expression of
FceRI is much higher on cDC than on pDC. What the functional
implications are for this difference in expression remains unclear.
The most intriguing finding of our study is the major difference
in the role of IgE in receptor expression. Whereas a direct
relationship between FceRI expression and IgE on both cDC and
pDC have been reported by others, we found that only pDC
FceRI expression correlated in a linear fashion with bound IgE
[21,24]. Our data did not show a relationship between serum IgE
and FceRI expression on pDC. This suggests free IgE may not
drive receptor expression, an event that depends singularly upon
level of bound IgE. This difference may be due to the low level of
expression of FceRI on pDC, and may explain differences between
how IgE drives FceRI expression on mast cells and basophils when
compared to pDC [20,25].
Unlike pDC, expression of FceRI on cDC correlated directly
with serum IgE levels. However, the relationship between bound
IgE and FceRI was more complex. When cell bound IgE was
below 12 fold MFI there was little effect of bound IgE on FceRI
expression. Once bound IgE levels crossed the threshold, a direct
relationship developed. At low levels of serum IgE (,34–42 kU/L)
there is rapid accumulation of bound IgE with little effect on
FceRI expression. At these low levels of IgE, a difference in
correlation of bound IgE and FceRI exists between sensitized and
non-sensitized subjects. Both responses are parabolic, however,
non-sensitized subjects tend to have an initial increase in FceRI
expression with increasing bound IgE (below 12 fold MFI).
Sensitized subjects had the exact opposite effect. Once serum IgE
levels reached 34–42 kU/L, corresponding to bound IgE levels of
12 fold MFI, both sensitized and non-sensitized subjects exhibited
a direct correlation between IgE and FceRI.
We have found a threshold effect of bound IgE on cDC FceRI.
The functional implications for this threshold effect are unclear; it
is inviting to speculate that FceRI has disparate functions at low
versus high IgE levels. Perhaps at lower levels FceRI acts as a
rheostat, similar to what is seen in rodents, where the receptor
functions as a mechanism for cellular recruitment and less for
antigen-uptake [5,6]. At higher levels of IgE, the receptor may
function more as a means for ‘‘antigen-focusing’’ [26]. It is beyond
the scope of this study to elucidate actual mechanisms behind this
phenomenon, but the functional implications of IgE regulation of
FceRI expression are tantalizing.
Our study had several limitations. First and foremost, we
utilized statistical modeling to evaluate our data, and, as a result, it
is important that these findings be validated in a second cohort.
Further, our sample size was relatively small and likely limited our
Figure 3. Expression of FceRI on pDC does not correlate with serum IgE or age of subject. Expression of FceRI on peripheral blood pDC
was determined by flow cytometry and compared to subject’s age (panel A) and serum IgE level (panel B). Data are presented as in Figure 1.
doi:10.1371/journal.pone.0032556.g003
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younger than 12 months of age, and we were unable to determine
if viral infection relates to induction of FceRI. Finally, defining
sensitization status by selected ImmunoCAP may not be ideal—
especially from a clinical perspective. However, given that our
results were mostly independent of sensitization status, we believe
this is not a major defect. Indeed, most of the limitations of our
study would only lessen our ability to define statistically significant
differences. Since we were able to document clear relationships
between IgE (serum and cell bound) and cDC and pDC expression
of FceRI despite these limitations, their presence only strengthen
the importance of our findings.
In summary, our results demonstrate the presence of FceRI on
peripheral blood cDC and pDC in children as young as 1 year old,
which is in contrast to what is seen in the rodent system. Our data
also provide evidence of differential regulation of FceRI on cDC
and pDC in children. With cDC a complex inter-relationship
between serum IgE, cell bound IgE, and expression of FceRI exists
that appears to hinge on an IgE level of 34–42 kU/L. The
functional significance of this relationship is unclear, and we do
not yet understand the mechanisms responsible for this relation-
ship. Future studies need to be undertaken to examine expression
of FceRI on cDC and how IgE modulates this receptor and cDC
function.
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